Laman UtamaEKSO • NASDAQ
add
Ekso Bionics Holdings Inc
Tutup sebelumnya
$0.67
Julat hari
$0.66 - $0.70
Julat tahun
$0.66 - $3.13
Permodalan pasaran
15.06J USD
Bilangan Purata
99.75K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(USD) | Sep 2024info | Perubahan T/T |
---|---|---|
Hasil | 4.13J | -10.38% |
Perbelanjaan pengendalian | 4.85J | -10.01% |
Pendapatan bersih | -2.07J | 38.42% |
Margin untung bersih | -50.18 | 31.30% |
Pendapatan bagi setiap syer | — | — |
EBITDA | -2.23J | 10.97% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(USD) | Sep 2024info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 8.29J | -16.55% |
Jumlah aset | 29.21J | -6.33% |
Jumlah liabiliti | 14.34J | -9.96% |
Jumlah ekuiti | 14.87J | — |
Syer tertunggak | 22.00J | — |
Harga kepada buku | 0.99 | — |
Pulangan pada aset | -23.48% | — |
Pulangan pada modal | -33.02% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(USD) | Sep 2024info | Perubahan T/T |
---|---|---|
Pendapatan bersih | -2.07J | 38.42% |
Tunai daripada operasi | -2.28J | 32.09% |
Tunai daripada pelaburan | -8.00K | 52.94% |
Tunai daripada pembiayaan | 4.69J | — |
Perubahan bersih dalam tunai | 2.41J | 171.42% |
Aliran tunai bebas | -1.11J | 57.80% |
Perihal
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. Wikipedia
CEO
Diasaskan
2005
Ibu pejabat
Tapak web
Pekerja
70